EcoDrugPlus

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSLBEG00000024128
Gene Symbol: LOC110000815
3 Cross references
181 Possible Orthologues:

Vascular Endothelial Growth Factor Receptor 3-Like

Ensembl ID : ENSLBEG00000028171
Gene Symbol: LOC109988057
3 Cross references
193 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSLBEG00000016950
Gene Symbol: VDR
3 Cross references
388 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSLBEG00000020673
Gene Symbol: LOC109993808
3 Cross references
392 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like Protein 1

Ensembl ID : ENSLBEG00000024408
Gene Symbol: LOC109987705
3 Cross references
190 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSLBEG00000008540
Gene Symbol: LOC109999322
2 Cross references
69 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSLBEG00000004682
Gene Symbol: LOC109988301
2 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSLBEG00000027269
Gene Symbol: LOC109985820
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSLBEG00000015418
Gene Symbol: LOC110000056
3 Cross references
167 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSLBEG00000015395
Gene Symbol: LOC110000062
3 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSLBEG00000015464
Gene Symbol: LOC110000061
4 Cross references
184 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-2-Like

Ensembl ID : ENSLBEG00000023051
Gene Symbol: LOC109980604
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).